Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Serous Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm
Serous Neoplasm

Histology

Serous Neoplasm

CI-CAN-00001502Explore in graph →

Non-malignant90 active trials11 evidence items

NCIt: C7074

Overview
Statistics
Survival
Genomics8
Variants & evidence11
Drugs10
Trials224
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (13)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–13 of 13 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
· Am J Obstet Gynecol · 2005 · PMID 15746676 · validated civic_curation pubmed
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
· Oncotarget · 2016 · PMID 26625204 · validated civic_curation pubmed
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
· J Clin Oncol · 2020 · PMID 32822286 · validated civic_curation pubmed
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.
· Int J Gynaecol Obstet · 2008 · PMID 18555254 · validated civic_curation pubmed
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
· J Clin Oncol · 2015 · PMID 26324360 · validated civic_curation pubmed
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.

Showing 1–13 of 13 publications

· Invest New Drugs · 2015 · PMID 26490654 · validated civic_curation pubmed

Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.

· Gynecol Oncol Rep · 2019 · PMID 30809568 · validated civic_curation pubmed

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

· Cancer Res · 2014 · PMID 24240700 · validated civic_curation pubmed

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

· Clin Cancer Res · 2017 · PMID 27663592 · validated civic_curation pubmed

Elkin et al. NPJ Genome Med 2021

· 2021 · PMID 34819508 · validated cbioportal_study pubmed

Manning-Geist et al. Clin Cancer Res. 2022

· 2022 · PMID 35443055 · validated cbioportal_study pubmed

TCGA, Nature 2011

· 2011 · PMID 21720365 · validated cbioportal_study pubmed